David A. Siegel Terns Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 316,836 shares of TERN stock, worth $2.74 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
316,836
Previous 109,600
189.08%
Holding current value
$2.74 Million
Previous $302,000
291.06%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TERN
# of Institutions
133Shares Held
84.2MCall Options Held
173KPut Options Held
89.5K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$70.7 Million2.36% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$65.5 Million1.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$64.9 Million0.99% of portfolio
-
Morgan Stanley New York, NY7.25MShares$62.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$59.7 Million5.45% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $326M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...